跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
泰立沙 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Lapatinib Ditosylate Tablets
Approved
化学药品
Lapatinib Ditosylate Tablets
GlaxoSmithKline AG
🇨🇳 National Medical Products Administration
Approval Date
Aug 9, 2021
Approval ID
8BYsaQLiSi2
Company
GlaxoSmithKline AG
Type
化学药品
Approval Details
Approval Id
8BYsaQLiSi2
Approval Number
国药准字HJ20171252
Generic Name
甲苯磺酸拉帕替尼片
Generic Name En
Lapatinib Ditosylate Tablets
Trade Name
泰立沙
Drug Type
化学药品
Dosage Form
片剂
Strength
0.25g
Reg Date
2021-08-09
Expired Date
2026-08-08
Company Name
GlaxoSmithKline AG
Company Address
Talstrasse 3-5, 3053 Münchenbuchsee, Switzerland
Production Company Name
glaxo operations uk limited,(trading as glaxo wellcome operations)
Production Company Address
Priory Street, Ware, Hertfordshire SG12 0DJ
Company Detail Path
/organization/glaxosmithkline-ag
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Aug 9, 2021
Approval ID
8BYsaQLiSi2
Type
化学药品
Back to NMPA Approvals